Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine
1. A next-generation live-attenuated yellow fever vaccine (vYF) demonstrated noninferior immunogenicity in contrast to the standard vaccine, with practically common seroconversion by one month after vaccination.
2. Safety profiles have been related between teams, with no vaccine-related severe hostile occasions noticed over one yr of follow-up.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Yellow fever stays a significant international well being menace, significantly in endemic areas of Africa and South America, the place outbreaks proceed to trigger substantial mortality and pressure vaccine provide chains. Existing vaccines are extremely efficient, however shortages throughout outbreaks have highlighted the necessity for scalable alternate options. This randomized managed trial evaluated a next-generation vaccine (vYF) designed to enhance manufacturing capability whereas sustaining efficacy. The examine discovered that vYF elicited an immune response comparable to the presently licensed vaccine, with practically all contributors reaching protecting antibody ranges throughout the first month. These responses endured by way of one yr, suggesting sturdy immunity. Importantly, the security profile of vYF carefully mirrored that of the standard vaccine, with principally delicate, transient hostile results and no main security issues recognized. Strengths of the examine included its randomized, observer-blinded design and its use of an energetic comparator which enhanced inside validity. One limitation was the restriction of enrollment to wholesome adults in a non-endemic setting, which can restrict generalizability to higher-risk populations corresponding to kids, older adults, or immunocompromised people. Additionally, the examine was not powered to detect uncommon hostile occasions, and follow-up stays ongoing for long-term sturdiness. Nevertheless, this examine suggests promising early efficacy and security of a next-generation live-attenuated yellow fever vaccine.
Click to read the study in NEJM
Relevant Reading: Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models
In-Depth [randomized controlled trial]: This section 2, observer-blinded randomized managed trial evaluated the immunogenicity and security of a next-generation live-attenuated yellow fever vaccine (vYF) in contrast with the licensed vaccine (YF-VAX). A complete of 568 wholesome adults aged 18 to 60 years have been enrolled throughout 11 facilities within the United States and randomized in a 2:1 ratio to obtain a single dose of vYF or YF-VAX. The main endpoint was seroconversion at day 29 amongst contributors with no prior yellow fever an infection or vaccination within the per-protocol inhabitants. Seroconversion occurred in 328 of 329 contributors (99.7%) within the vYF group and 155 of 156 contributors (99.4%) within the YF-VAX group, yielding a between-group distinction of 0.3 proportion factors (95% confidence interval [CI]-1.2 to 3.2). Neutralizing antibody geometric imply titers rose considerably by day 29 in each teams, peaking at roughly 1:2654 for vYF and 1:3147 for YF-VAX in contributors with out prior publicity and remaining above the protecting threshold (≥1:10) in additional than 97% of each teams at 1 yr. In a subgroup evaluated at day 11, protecting titers have been noticed in a smaller proportion of vYF recipients versus YF-VAX recipients (38% versus 61%); However, the examine was not powered to assess noninferiority at this early time level. Requested hostile occasions occurred in 56.7% of contributors receiving vYF and 61.1% receiving YF-VAX, mostly headache (36.5% vs. 37.8%) and injection-site ache (28.7% vs. 31.4%). Serious hostile occasions have been uncommon and never thought-about associated to vaccination. These findings display acceptable early efficacy and security of a next-generation yellow fever vaccine.
Image: PS
©2026 2 Minute Medicine, Inc.. All rights reserved. No works could also be reproduced with out expressed written consent from 2 Minute Medicine, Inc.. Inquire about licensing here. No article must be constructed as medical recommendation and isn’t meant as such by the authors or by 2 Minute Medicine, Inc.
